Teknoloji yönetimi süreci üzerine bir çalışma: Türk otomotiv endüstrisi yan sanayii

Türk otomotiv yan sanayiinde teknoloji yönetimi süreci üzerine ampirik bir çalışmanın özeti olan bu makalede, Türk otomotiv yan sanayiindeki teknoloji yönetimi uygulamaları ele alınmış ve değerlendirilmiştir. Teknoloji yönetimi seviyesini yükseltmek için sunulan uygulamaların, teknik ve yaklaşımların temel amacı, teknolojiyi rekabetçi bir silah olarak kullanabilmektir. Bu araştırma, teknoloji yönetiminde süreç modeli çerçevesinde organize edilmiştir. Teknoloji yönetiminde süreç modeli; teknoloji belirlenmesi, seçimi, edinimi, kullanımı, korunumu ve sonlandırılmasını içermektedir. Süreci bütün kısımları ile inceleyen ve 21 şirketi kapsayan bir anket çalışması yapılmış ve sonuçları burada sunulmuştur

Comparison of 3d reformat computed tomography images using different softwares: do they have an incremental value in 3D imaging?

Three dimensional (3D) imaging gained an important diagnostic role because of providing the precise diagnosis in computed tomography (CT) studies. Various 3D softwares such as; VitreaWorkstation - Toshiba, Japan; OsiriX-Switzerland; Volume Viewer-General Electric, USA have been manufactured to improve its diagnostic ability. Providing the deep sense and dimensional perception, the aim of this prospective study is to compare the native 3D (N3D) CT images with 2 anaglyph images by using different softwares and delineate their contribution to 3D CT imaging

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17–85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10–0.31). Overall, vaccination against SARS-CoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11–0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.Fil: Efe, Cumali. Harran University Hospital; TurquíaFil: Taşçılar, Koray. Universitat Erlangen-Nuremberg; AlemaniaFil: Gerussi, Alessio. San Gerardo Hospital; Italia. Università degli Studi di Milano; ItaliaFil: Bolis, Francesca. Università degli Studi di Milano; ItaliaFil: Lammert, Craig. University School of Medicine; Estados UnidosFil: Ebik, Berat. Gazi Yaşargil Education and Research Hospital; TurquíaFil: Stättermayer, Albert Friedrich. Medizinische Universität Wien; AustriaFil: Cengiz, Mustafa. Gülhane Training and Research Hospital; TurquíaFil: Gökçe, Dilara Turan. Ankara City Hospital; TurquíaFil: Cristoferi, Laura. Università degli Studi di Milano; Italia. San Gerardo Hospital; ItaliaFil: Peralta, Mirta. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; Argentina. Latin American Liver Research Educational And Awareness Network; ArgentinaFil: Massoumi, Hatef. Montefiore Medical Center; Estados UnidosFil: Montes, Pedro. Hospital Nacional Daniel Alcides Carrión; PerúFil: Cerda, Eira. Hospital Central Militar, Mexico City; MéxicoFil: Rigamonti, Cristina. Università del Piemonte Orientale UPO,; Italia. Azienda Ospedaliera Maggiore Della Carita Di Novara; ItaliaFil: Yapalı, Suna. Acıbadem University School of Medicine; TurquíaFil: Adali, Gupse. Umraniye Education and Research Hospital; TurquíaFil: Çalışkan, Ali Rıza. Adiyaman Üniversitesi; TurquíaFil: Balaban, Yasemin. Hacettepe Üniversitesi; TurquíaFil: Eren, Fatih. Uludag University; TurquíaFil: Eşkazan, Tuğçe. Cerrahpaşa School of Medicine; TurquíaFil: Barutçu, Sezgin. University of Gaziantep Medical Faculty; TurquíaFil: Lytvyak, Ellina. University of Alberta; CanadáFil: Zazueta, Godolfino Miranda. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Kayhan, Meral Akdogan. Gülhane Training and Research Hospital; TurquíaFil: Heurgue Berlot, Alexandra. Chu de Reims; FranciaFil: De Martin, Eleonora. Universite Paris-Saclay;Fil: Yavuz, Ahmet. Necmettin Erbakan University; TurquíaFil: Bıyık, Murat. Necmettin Erbakan University; TurquíaFil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina. Universidad Austral; Argentina. Latin American Liver Research Educational and Awareness Network; Argentin

SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine